<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells (CTCs) released into blood from primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> reflect the current status of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> genotypes, which are prone to changes </plain></SENT>
<SENT sid="1" pm="."><plain>Here we performed the first comprehensive genomic profiling of CTCs using array-CGH and next-generation sequencing </plain></SENT>
<SENT sid="2" pm="."><plain>We used the FDA-cleared CellSearchTM system, which detected CTCs in 21 of 37 patients (range 1-202 per 7.5 ml sample) with stage IV colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In total, we were able to isolate 37 intact CTCs from 6 patients and identified in those multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-associated copy number changes, many of which were also present in the respective <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We then used massive parallel sequencing of a panel of 68 CRC-associated genes to compare the mutation spectrum in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and the corresponding CTCs from two of these patients </plain></SENT>
<SENT sid="5" pm="."><plain>Mutations in known driver genes (e.g., APC, KRAS, or PIK3CA) found in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> were also detected in corresponding CTCs </plain></SENT>
<SENT sid="6" pm="."><plain>However, we also observed mutations exclusively in CTCs </plain></SENT>
<SENT sid="7" pm="."><plain>To address whether these mutations were derived from a small subclone in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> or represented new variants of metastatic cells, we performed additional deep sequencing of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and applied a customized statistical algorithm for analysis </plain></SENT>
<SENT sid="8" pm="."><plain>We found that most mutations initially found only in CTCs were also present at subclonal level in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from the same patient </plain></SENT>
<SENT sid="9" pm="."><plain>Our study paves the way to use CTCs as a liquid biopsy in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>